Loyal, a San Francisco, CA-based clinical-stage animal health company, has raised $100 million in a Series C funding round led by age1.
The round also saw participation from Baillie Gifford alongside existing investors.
The funding round raised the company’s total to over $250 million since its founding in late 2019.
Read More:Trener Robotics Raises $32M in Series A Funding
The company will use the new funding to grow its team, build distribution channels, and prepare for the market launch of its first drug to extend canines’ lifespans.
The financing comes as Loyal advances toward XCA for LOY-002. Over the past year, the company has completed two of the three main requirements for XCA and market launch and finished enrolling 1,300 dogs in its pivotal STAY study across 70 veterinary clinics—the largest clinical trial in veterinary history. These milestones highlight Loyal’s scientific and regulatory rigour and bring the company closer to market readiness.
Loyal is a clinical-stage animal health company developing lifespan-extending drugs for dogs. Its lead program, LOY-002, is a daily prescription pill designed to extend the healthy lifespan of senior dogs by targeting the metabolic drivers of aging. Loyal has completed the
Reasonable Expectation of Effectiveness (RXE) and Target Animal Safety (TAS) requirements, meeting two of the three main steps for Expanded Conditional Approval (XCA). If approved, LOY-002 could become the first FDA-approved drug to extend lifespan in any species.
“Our mission at Loyal is to help dogs live longer, healthier lives,” said Loyal Founder & CEO Celine Halioua. “We’re closer than ever to achieving our goal: an FDA-approved drug to extend canine lifespan. This funding will support our team in completing the remaining FDA requirements and bringing our lead program to market.”
“I’ve been fortunate to know Celine since 2018 and watch the team’s relentless execution as an investor,” said Alex Colville, Co-founder and General Partner of age1. “Loyal is driving a scientific and cultural shift toward proactive aging therapies. Few fully appreciate the impact so far—or the impact yet to come. Our understanding and approach to aging will never be the same.”
“Celine and her team are changing how preventive care is done in veterinary medicine,” said Tom Slater, partner at Baillie Gifford. “Helping dogs live longer, healthier lives is important to many families. With strong scientific work and a clear regulatory plan, Loyal is well-positioned to build a successful business in a growing market.”
The last major step for FDA Expanded Conditional Approval (XCA) is underway, and the company aims to submit it for review later this year.
About Loyal
Founded in 2020 by CEO Celine Halioua, Loyal is an animal health company developing the first drugs to help dogs live longer healthier lives. With over $250 million raised so far, Loyal focuses on extending dogs’ lifespans and improving their quality of life by targeting the underlying causes of aging. Building on decades of research, the company’s team of experts in canine health and longevity is dedicated to advancing this work and developing better ways to measure and improve aging in dogs. Loyal currently has three drugs in development and is progressing toward approval from the FDA’s Center for Veterinary Medicine.
Read More:ManageMy Raises $45M in Funding
